Great work viridi. Those are significant numbers and really suggest the importance of a consideration of 42 day mortality. My girlfriend is a palliative care nurse and sees in end-of-life patients both the fierce will to survive as well as the ability of modern medicine to keep the shell of a body alive. Both factors might well skew the 28 day numbers of the CD12 trial and I share your feeling that we are waiting for 42 day data. Which bodes well for us.

That Javitt and RLFTF are waiting on 60 day data for intravenous rlf-100 seems like a stretch. Like they are playing a weak hand. I wonder if the inhaled version, earlier in the course of the disease, will make it a useful option for the M/M population.

I still hope/think that CD12 will achieve statistical significance at 28 days. If nothing else for bragging rights--the only company that completed a phase III trial in severe/critical covid with mortality benefit as the primary endpoint. Without changing the goalposts along the way!

Apparently if I recall correctly there are only a handful of FDA drug trials in history that have provided evidence of statistically significant mortality benefit. I saw that comment somewhere recently but didn't archive it. Sure would be nice for Cytodyn to join that club, establish some major credibility and quiet the doubters. And start saving lives of course.